MRAP2 Inhibitors
Chemical inhibitors of the MRAP2 protein function by interacting with beta-adrenergic receptors, which are part of the signaling pathways that MRAP2 modulates. Alprenolol and propranolol, both non-selective beta-adrenergic receptor antagonists, can inhibit the activation of receptors that MRAP2 interacts with, leading to a decrease in the signaling cascade associated with MRAP2. Similarly, carvedilol, with its non-selective beta-blocking and additional alpha-1 blocking activity, can reduce the functional activity of MRAP2 by inhibiting the signaling of beta-adrenergic receptors involved in MRAP2's pathway. Labetalol, serving as both an alpha and a non-selective beta-adrenergic receptor blocker, acts to impair the signaling pathways that MRAP2 interacts with, diminishing MRAP2's role. Nadolol, another non-selective beta-adrenergic receptor antagonist, can decrease the activity in the signaling pathways involving MRAP2, thus inhibiting the protein's function.
Furthermore, timolol and sotalol, also non-selective beta-adrenergic receptor antagonists, can decrease the activity in the signaling pathways where MRAP2 is functional, leading to inhibition of MRAP2's role. On the other hand, selective beta-1 adrenergic receptor blockers such as metoprolol, atenolol, bisoprolol, and esmolol can specifically inhibit the signaling in pathways that involve MRAP2 in a more targeted manner. Metoprolol's selective inhibition of beta-1 adrenergic receptors can reduce the signaling in pathways that MRAP2 is part of, whereas atenolol and bisoprolol can lead to inhibition of the signaling cascades in which MRAP2 is involved. Esmolol's blocking of beta-1 receptors can inhibit the downstream signaling that MRAP2 is associated with. Lastly, nebivolol's selective beta-1 blockade, coupled with additional vasodilatory effects, can lead to a decrease in the activity of signaling pathways involving MRAP2, inhibiting the protein's functional role within these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Alprenolol is a non-selective beta-adrenergic receptor antagonist. MRAP2 has been shown to interact with beta-adrenergic receptors. Alprenolol can inhibit the activation of these receptors, which could lead to a decrease in the signaling cascade that MRAP2 is involved in, thus functionally inhibiting MRAP2's role in this pathway. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is another non-selective beta-adrenergic receptor antagonist. By blocking beta-adrenergic receptors, propranolol would inhibit the signaling cascade that MRAP2 is a part of, leading to a functional inhibition of MRAP2's associated activities within that pathway. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking activity. It can inhibit the signaling of beta-adrenergic receptors, which are part of the pathway that MRAP2 modulates. This inhibition can reduce the functional activity of MRAP2 within this signaling cascade. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Labetalol acts as both a selective alpha-adrenergic receptor blocker and a non-selective beta-adrenergic receptor blocker. By inhibiting these receptors, labetalol would impair the signaling pathways that MRAP2 is known to interact with, leading to a reduction in MRAP2's functional role within these pathways. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol is a non-selective beta-adrenergic receptor antagonist. Its inhibition of beta-adrenergic receptors can decrease the signaling that involves MRAP2, thereby inhibiting the protein's function in processes regulated by these receptors. | ||||||
Timolol maleate | 26921-17-5 | sc-507468 | 100 mg | $500.00 | ||
Timolol is a non-selective beta-adrenergic receptor antagonist. By inhibiting beta-adrenergic receptors, it can decrease the activity in the signaling pathways where MRAP2 is functional, leading to inhibition of MRAP2's role in these pathways. | ||||||
Sotalol hydrochloride | 959-24-0 | sc-203699 sc-203699A | 10 mg 50 mg | $68.00 $251.00 | 3 | |
Sotalol is a non-selective beta-adrenergic receptor antagonist with additional antiarrhythmic properties. Sotalol's inhibition of beta-adrenergic receptors can functionally inhibit the signaling pathways that involve MRAP2, reducing the protein's functional activity. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol is a selective beta-1 adrenergic receptor blocker. By selectively inhibiting beta-1 adrenergic receptors, metoprolol could reduce the signaling in pathways that MRAP2 is part of, thereby inhibiting MRAP2's functionality in these pathways. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol is a selective beta-1 adrenergic receptor antagonist. It can inhibit the function of these receptors and thus inhibit the signaling pathways that involve MRAP2, reducing the functional role of MRAP2 in these pathways. | ||||||
Bisoprolol | 66722-44-9 | sc-278792 | 25 mg | $208.00 | ||
Bisoprolol is a selective beta-1 adrenergic receptor antagonist. Its action to block beta-1 receptors can lead to inhibition of the signaling cascades in which MRAP2 is involved, thus functionally inhibiting MRAP2. | ||||||